PP2 [172889-27-9]

Referentie HY-13805-5mg

Formaat : 5mg

Merk : MedChemExpress


Description

PP2 is a reversible and ATP-competitive Src family kinases inhibitor with IC50s of 4 and 5 nM for Lck and Fyn, respectively.

IC50 & Target

IC50: 4 nM (Lck), 5 nM (Fyn)[1]

Cellular Effect
Cell Line Type Value Description References
8701-BC IC50
61.8 μM
Compound: PP2
In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay
In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay
[PMID: 15027847]
8701-BC IC50
61.8 μM
Compound: PP2
Antiproliferative activity against 8701-BC cells
Antiproliferative activity against 8701-BC cells
[PMID: 16509573]
A-431 IC50
131 μM
Compound: PP2
Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178)
Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178)
[PMID: 15109642]
A-431 IC50
17 μM
Compound: PP2
Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21)
Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21)
[PMID: 15109642]
A-431 IC50
22 μM
Compound: PP2
Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38)
Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38)
[PMID: 15109642]
A-431 IC50
32 μM
Compound: PP2
Tested for antiproliferative activity against human A431 cells
Tested for antiproliferative activity against human A431 cells
[PMID: 15109642]
A-431 IC50
32.2 μM
Compound: PP2
Antiproliferative activity against A431 cells
Antiproliferative activity against A431 cells
[PMID: 16509573]
A549 IC50
0.01 μM
Compound: PP2
Growth inhibition of human A549 cells
Growth inhibition of human A549 cells
[PMID: 28814374]
Jurkat IC50
4 nM
Compound: PP2
Inhibition of p56 Lck tyrosine kinase in Jurkat cells where p56lck autophosphorylation is inhibited.
Inhibition of p56 Lck tyrosine kinase in Jurkat cells where p56lck autophosphorylation is inhibited.
10.1016/S0960-894X(97)00034-6
K562 IC50
25 μM
Compound: 8, PP2
Antiproliferative activity against human K562 cells
Antiproliferative activity against human K562 cells
[PMID: 18257513]
KU812 cell line IC50
45 μM
Compound: 8, PP2
Antiproliferative activity against human KU812 cells
Antiproliferative activity against human KU812 cells
[PMID: 18257513]
MEG-01 IC50
17 μM
Compound: 8, PP2
Antiproliferative activity against human MEG01 cells
Antiproliferative activity against human MEG01 cells
[PMID: 18257513]
SAOS-2 IC50
8.07 μM
Compound: PP2
Cytotoxicity against human Saos2 cells after 48 hrs by MTT assay
Cytotoxicity against human Saos2 cells after 48 hrs by MTT assay
[PMID: 23932070]
SAOS-2 IC50
8.1 μM
Compound: PP2
Antiproliferative activity against human SaOS2 cells assessed as cellular viability
Antiproliferative activity against human SaOS2 cells assessed as cellular viability
[PMID: 17929792]
SH-SY5Y IC50
6.1 μM
Compound: PP2
Antiproliferative activity against human SH-SY5Y cells assessed as cell viability after 72 hrs by XTT assay
Antiproliferative activity against human SH-SY5Y cells assessed as cell viability after 72 hrs by XTT assay
[PMID: 21856155]
T-cell IC50
600 nM
Compound: K00048, AG-1879
Inhibition of adhesion kinase in human T cells
Inhibition of adhesion kinase in human T cells
[PMID: 18077363]
T-cell IC50
600 nM
Compound: K00048, AG-1879
Inhibition of tyrosine phosphorylation in human T cells
Inhibition of tyrosine phosphorylation in human T cells
[PMID: 18077363]
In Vitro

At 10 μM, the effect of PP2 on cellular proliferation is not significant, indicating that, at this low concentration, the effect of PP2 on Gemcitabine cytotoxicity does not simply reflect a direct antiproliferative effect, but rather a potentiation of Gemcitabine-induced cytotoxicity. Above 20 μM, growth is increasingly suppressed, a finding consistent with reports in other human cancer cell lines. Although 10 μM PP2 is used in our study, at higher concentrations PP2 is reported to inhibit other intracellular kinases[2]. PP2 is the most widely used commercially available Src family kinase inhibitor. PP2 inhibits Src family kinase activity with IC50 of ~5 nM in vitro, concentrations to 10 μM are often necessary to achieve complete Src family kinase inhibition in cell culture[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Solvant et solubilité
In Vitro: 

DMSO : 50 mg/mL (165.69 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.3138 mL 16.5689 mL 33.1378 mL
5 mM 0.6628 mL 3.3138 mL 6.6276 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 3 mg/mL (9.94 mM); Clear solution

    This protocol yields a clear solution of ≥ 3 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (30.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Pureté et documentation
Références

Misschien heeft u ook interesse in de volgende producten:



Referentie
Beschrijving
Cond.
Price Bef. VAT
A3017-100mg
 100mg 
HY-10459-5mg
 5mg 
HY-10219-25mg
 25mg